Devin Quinlan

Devin Quinlan is a biotech venture investor based in Cambridge, MA. He earned a B.S. in Bioengineering from UCLA (2008–2012) and a Ph.D. in Biological Engineering from MIT (2012–2017), where he worked in the lab of Ram Sasisekharan. His doctoral thesis focused on uncovering structure–function relationships of antibodies targeting viral antigens, including the Ebola and Zika viruses — work reflected in his peer-reviewed publications (he maintains a Google Scholar profile). His scientific expertise spans glycobiology/glycomics, virology, structural biology, and protein engineering.

After an internship with the firm, Quinlan joined MPM Capital / BioImpact Capital full-time in 2018 and built his investing career there, rising from Senior Associate to Principal at what is now MPM BioImpact — a long-running, biotech-dedicated investment firm (nearly three decades of history) managing roughly $3B+ across early-stage venture, public/private impact, and public-equities strategies. In that role he supported multiple investments across diverse therapeutic areas and took company-level governance roles.

He has since moved to Curie.Bio, the seed-stage biotech fund and therapeutics accelerator founded by Alexis Borisy, where his public bio describes him as a "Biotech VC @ Curie.Bio Breakout Fund." Curie.Bio blends seed venture capital with a hands-on, industry-grade drug-development accelerator; its Breakout Fund ($380M, announced June 2024) backs follow-on rounds that carry seed-stage companies through clinical trials, complementing its seed funds (a second seed fund of ~$340M was announced in January 2025).

• Invests exclusively in biotechnology / therapeutics, backing scientist-founders with differentiated modalities — consistent with his own training in antibody and protein engineering.
• Stage: seed and early venture, with Curie.Bio's Breakout Fund extending support into clinical development; at MPM his mandate spanned Seed, Series A, and Series B.
• Check size: modest early checks at MPM (~$1.5M sweet spot, up to ~$5M); Curie.Bio writes larger institutional rounds (~$5M–$15M).
• What makes them say yes: strong underlying science with a credible path to in-vivo proof-of-concept or a development candidate, paired with a founding team Curie.Bio can accelerate operationally. Curie.Bio is highly selective (reportedly a sub-1% acceptance rate), so scientific differentiation and milestone clarity matter most.